Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of C1013G/CXCR4-associated Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody

Treatment of C1013G/CXCR4-associated Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody

US Patent 11220548 · Granted Jan 11, 2022

Estimated economic value: $723,761,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Proteolysis targeting chimeric molecules (PROTACs) with functional handles and u2024
Human monoclonal antibodies that bind CXCR4 and uses thereof2022
Genetic abnormalities in plasma cell dyscrasias2021
Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibod2021
Interferon receptor 1 antibodies and their uses2021
Monoclonal antibodies to programmed death 1 (PD-1)2019
Treatment of hematologic malignancies with an anti-CXCR4 antibody2019
Interferon receptor 1 antibodies and their uses2019
Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodie2019
Treatment of C1013G/CXCR4-associated waldenstroöm's macroglobulinemia with an an2019
Treatment of C1013G/CXCR4-associated waldenstroöm's macroglobulinemia with an an2019
Treatment of C1013G/CXCR4-associated waldenstroöm's macroglobulinemia with an an2019